Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $7.7100 (-1.78%) ($7.5700 - $7.8900) on Mon. Oct. 7, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.79% (three month average) | RSI | 21 | Latest Price | $7.7100(-1.78%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.7% a day on average for past five trading days. | Weekly Trend | FOLD declines -7.6% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Normal for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(60%) XBI(56%) IWO(55%) IWM(52%) IWC(50%) | Factors Impacting FOLD price | FOLD will decline at least -1.395% in a week (0% probabilities). VIXM(-33%) VXX(-19%) TLT(-14%) TIP(-1%) UNG(-0%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.395% (StdDev 2.79%) | Hourly BBV | 0 () | Intraday Trend | -1.3% | | | |
|
1 - 5 Day Possible Target | $-7.98(-203.5%) | Resistance Level | $8.91 | 5 Day Moving Average | $8.1(-4.81%) | 10 Day Moving Average | $8.22(-6.2%) | 20 Day Moving Average | $8.91(-13.47%) | To recent high | -41.8% | To recent low | 0% | Market Cap | $1.991b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |